SynthesisCurrent drug targets2026
Marine Microbes: A Source of Novel Antibiotics against Antimicrobial-resistant (AMR) Pathogens: A Systematic Review.
Synthesis in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Biotechnological Applications of Marine Bacteria.Biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe development of novel antibiotics is urgently needed due to the rise in multidrug-resistant (MDR) infections globally. Marine microorganisms have emerged as unexplored sources of bioactive compounds with unique mechanisms to combat antimicrobial resistance (AMR).
methodsThis review summarizes peer-reviewed and recent research from PubMed, Scopus, and Web of Science to evaluate the scope of marine-derived metabolites against AMR pathogens. The focus was on studies describing antimicrobial metabolites produced by marine actinomycetes, bacteria, and fungi. Studies involving non-resistant pathogens or non-marine sources were excluded.
resultsThe review identifies various secondary metabolites, including peptides, polyketides, macrolides, fatty acid amines, equisetin, and aminolipids. These compounds target AMR pathogens such as MRSA, VRE, and VRSE. Marine actinomycetes-including Streptomyces spp., Micromonospora spp., and Verrucosispora spp.-are key producers of antimicrobial compounds. Likewise, marine bacterial species such as Bacillus spp., Aequorivita spp., and Zobellia galactanivorans, as well as fungal species like Penicillium spp. and Fusarium spp., produce bioactive compounds. DISCUSSION: These findings highlight the potential of marine microbes as sources of novel antibiotics. Despite this potential, several limitations persist, including scalability issues, the noncultivability of many microbes, toxicology concerns, source-dependent variability, and insufficient in vivo validation. These challenges can be addressed by integrating modern omics technologies to advance drug discovery for AMR.
conclusionThis review underscores marine microbes as promising sources in the fight against AMR. To unlock their full potential, greater interdisciplinary collaboration is needed to develop sustainable solutions, accelerate antibiotic discovery, and address the global AMR crisis.
Indexed as
Identifiers
41510723What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.